Jeff Myers1, Audrey Kim, Jamie Flanagan, Debbie Selby. 1. Division of Palliative Care, Department of Family and Community Medicine, University of Toronto, Palliative Care Consult Team, Sunnybrook Health Sciences Centre, Rm H336, 2075 Bayview Avenue, Toronto, Ontario, M4N 3 M5, Canada, jeff.myers@sunnybrook.ca.
Abstract
PURPOSE: Previous studies have examined the association between the Palliative Performance Scale (PPS) and survival duration; however, few have examined patients with incurable cancer in the outpatient setting. In addition to exploring this association further, the purpose of this study was to identify key PPS markers that could serve as triggers to signify the need for key care discussions. METHODS: Study subjects were followed prospectively from the time of referral for a specialist palliative care consultation until death. PPS ratings and survival estimates were determined for each visit. RESULTS: For the final study population of 368 patients, at baseline, the median PPS rating was 60. Overall median and mean survival duration were approximately 4 and 6 months, respectively. Median survival duration for patients with PPS ratings of 70, 60, and 50 were found to be approximately 6, 3, and 2 months, respectively. Twenty-four percent of all survival estimates were found to be accurate. CONCLUSIONS: Given the ongoing challenge of inaccurate survival estimates, this data suggests what may be of greatest clinical utility is to use specific PPS ratings as triggers for key care discussions among patients with incurable and progressive cancer.
PURPOSE: Previous studies have examined the association between the Palliative Performance Scale (PPS) and survival duration; however, few have examined patients with incurable cancer in the outpatient setting. In addition to exploring this association further, the purpose of this study was to identify key PPS markers that could serve as triggers to signify the need for key care discussions. METHODS: Study subjects were followed prospectively from the time of referral for a specialist palliative care consultation until death. PPS ratings and survival estimates were determined for each visit. RESULTS: For the final study population of 368 patients, at baseline, the median PPS rating was 60. Overall median and mean survival duration were approximately 4 and 6 months, respectively. Median survival duration for patients with PPS ratings of 70, 60, and 50 were found to be approximately 6, 3, and 2 months, respectively. Twenty-four percent of all survival estimates were found to be accurate. CONCLUSIONS: Given the ongoing challenge of inaccurate survival estimates, this data suggests what may be of greatest clinical utility is to use specific PPS ratings as triggers for key care discussions among patients with incurable and progressive cancer.
Authors: Francis Lau; Michael Downing; Mary Lesperance; Nicholas Karlson; Craig Kuziemsky; Ju Yang Journal: J Pain Symptom Manage Date: 2009-01-26 Impact factor: 3.612
Authors: Jennifer S Temel; Joseph A Greer; Sonal Admane; Emily R Gallagher; Vicki A Jackson; Thomas J Lynch; Inga T Lennes; Connie M Dahlin; William F Pirl Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1998-06-03 Impact factor: 56.272
Authors: Michael J Hochman; Arif H Kamal; Steven P Wolf; Greg P Samsa; David C Currow; Amy P Abernethy; Thomas W LeBlanc Journal: J Pain Symptom Manage Date: 2016-09-20 Impact factor: 3.612
Authors: Eli L Diamond; David Russell; Maria Kryza-Lacombe; Kathryn H Bowles; Allison J Applebaum; Jeanne Dennis; Lisa M DeAngelis; Holly G Prigerson Journal: Neuro Oncol Date: 2015-08-09 Impact factor: 12.300
Authors: Roberta I Jordan; Matthew J Allsop; Yousuf ElMokhallalati; Catriona E Jackson; Helen L Edwards; Emma J Chapman; Luc Deliens; Michael I Bennett Journal: BMC Med Date: 2020-11-26 Impact factor: 8.775